{"pmid":32372809,"pmcid":"PMC7195036","title":"Facing two deadly viruses.","text":["Facing two deadly viruses.","As covid-19 begins to take hold, the Democratic Republic of the Congo has detected its first new Ebola cases in months, reports Peter Yeung.","New Sci","Yeung, Peter","32372809"],"abstract":["As covid-19 begins to take hold, the Democratic Republic of the Congo has detected its first new Ebola cases in months, reports Peter Yeung."],"journal":"New Sci","authors":["Yeung, Peter"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32372809","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/S0262-4079(20)30743-0","locations":["Congo"],"countries":["Congo"],"countries_codes":["COG|Congo"],"topics":["General Info"],"weight":1,"_version_":1666138496424738816,"score":9.490897,"similar":[{"pmid":32500116,"pmcid":"PMC7236423","title":"Leveraging investments in Ebola preparedness for COVID-19 in Sub-Saharan Africa.","text":["Leveraging investments in Ebola preparedness for COVID-19 in Sub-Saharan Africa.","The emergence of SARS-CoV-2 in China and transmission to more than 80 territories worldwide, including nine countries in Africa, presents a delicate situation for low-resource settings. Countries in Eastern and Central Africa have been on high alert since mid-2018 in anticipation of regional spread of the Ebola virus from the Democratic Republic of Congo. Significant investment has been made to support enhanced surveillance at point of entry and hospitals, infection control practices, clinical case management, and clinical research. With a new threat on the horizon, African countries have an opportunity to leverage the existing capacities for Ebola preparedness to brace for the imminent threat.","AAS Open Res","Ayebare, Rodgers","Waitt, Peter","Okello, Stephen","Kayiira, Mubaraka","Atim Ajok, Maureen","Nakatudde, Irene","Bhadelia, Nahid","Lamorde, Mohammed","32500116"],"abstract":["The emergence of SARS-CoV-2 in China and transmission to more than 80 territories worldwide, including nine countries in Africa, presents a delicate situation for low-resource settings. Countries in Eastern and Central Africa have been on high alert since mid-2018 in anticipation of regional spread of the Ebola virus from the Democratic Republic of Congo. Significant investment has been made to support enhanced surveillance at point of entry and hospitals, infection control practices, clinical case management, and clinical research. With a new threat on the horizon, African countries have an opportunity to leverage the existing capacities for Ebola preparedness to brace for the imminent threat."],"journal":"AAS Open Res","authors":["Ayebare, Rodgers","Waitt, Peter","Okello, Stephen","Kayiira, Mubaraka","Atim Ajok, Maureen","Nakatudde, Irene","Bhadelia, Nahid","Lamorde, Mohammed"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500116","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.12688/aasopenres.13052.1","keywords":["covid-19 preparedness","coronavirus","ebola","sars-cov-2"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1668804508797370368,"score":139.68105},{"pmid":32431285,"title":"Recommendations for the COVID-19 Response at the National Level Based on Lessons Learned from the Ebola Virus Disease Outbreak in the Democratic Republic of the Congo.","text":["Recommendations for the COVID-19 Response at the National Level Based on Lessons Learned from the Ebola Virus Disease Outbreak in the Democratic Republic of the Congo.","The tenth outbreak of Ebola virus disease (EVD) in North Kivu, the Democratic Republic of the Congo (DRC), was declared 8 days after the end of the ninth EVD outbreak, in the Equateur Province on August 1, 2018. With a total of 3,461 confirmed and probable cases, the North Kivu outbreak was the second largest outbreak after that in West Africa in 2014-2016, and the largest observed in the DRC. This outbreak was difficult to control because of multiple challenges, including armed conflict, population displacement, movement of contacts, community mistrust, and high population density. It took more than 21 months to control the outbreak, with critical innovations and systems put into place. We describe systems that were put into place during the EVD response in the DRC that can be leveraged for the response to the current COVID-19 global pandemic.","Am J Trop Med Hyg","Mobula, Linda Meta","Samaha, Hadia","Yao, Michel","Gueye, Abdou Salam","Diallo, Boubacar","Umutoni, Chantal","Anoko, Julienne","Lokonga, Jean-Pierre","Minikulu, Luigi","Mossoko, Mathias","Bruni, Emanuele","Carter, Simone","Jombart, Thibaut","Fall, Ibrahima Soce","Ahuka-Mundeke, Steve","32431285"],"abstract":["The tenth outbreak of Ebola virus disease (EVD) in North Kivu, the Democratic Republic of the Congo (DRC), was declared 8 days after the end of the ninth EVD outbreak, in the Equateur Province on August 1, 2018. With a total of 3,461 confirmed and probable cases, the North Kivu outbreak was the second largest outbreak after that in West Africa in 2014-2016, and the largest observed in the DRC. This outbreak was difficult to control because of multiple challenges, including armed conflict, population displacement, movement of contacts, community mistrust, and high population density. It took more than 21 months to control the outbreak, with critical innovations and systems put into place. We describe systems that were put into place during the EVD response in the DRC that can be leveraged for the response to the current COVID-19 global pandemic."],"journal":"Am J Trop Med Hyg","authors":["Mobula, Linda Meta","Samaha, Hadia","Yao, Michel","Gueye, Abdou Salam","Diallo, Boubacar","Umutoni, Chantal","Anoko, Julienne","Lokonga, Jean-Pierre","Minikulu, Luigi","Mossoko, Mathias","Bruni, Emanuele","Carter, Simone","Jombart, Thibaut","Fall, Ibrahima Soce","Ahuka-Mundeke, Steve"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32431285","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.4269/ajtmh.20-0256","locations":["North Kivu","North Kivu","West Africa"],"topics":["Prevention"],"weight":1,"_version_":1667342288329637888,"score":136.1268},{"pmid":32348165,"title":"Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.","text":["Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.","The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise that requires substantial upfront planning and offers no guarantee of success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the Congo, as well as the 2009 H1N1 influenza, 2014-2016 Ebola, and 2015-16 Zika outbreaks preceding it, we offer our perspective on challenges facing EID vaccine development and recommend additional solutions to prioritize in the near term. The 6 recommendations focus on reducing vaccine development timelines and increasing business certainty to reduce risks for companies. The global health security community has an opportunity to build on the current momentum to design a sustainable model for EID vaccines.","Health Secur","Billington, John","Deschamps, Isabelle","Erck, Stanley C","Gerberding, Julie L","Hanon, Emmanuel","Ivol, Sabrina","Shiver, John W","Spencer, Julia A","Van Hoof, Johan","32348165"],"abstract":["The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise that requires substantial upfront planning and offers no guarantee of success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the Congo, as well as the 2009 H1N1 influenza, 2014-2016 Ebola, and 2015-16 Zika outbreaks preceding it, we offer our perspective on challenges facing EID vaccine development and recommend additional solutions to prioritize in the near term. The 6 recommendations focus on reducing vaccine development timelines and increasing business certainty to reduce risks for companies. The global health security community has an opportunity to build on the current momentum to design a sustainable model for EID vaccines."],"journal":"Health Secur","authors":["Billington, John","Deschamps, Isabelle","Erck, Stanley C","Gerberding, Julie L","Hanon, Emmanuel","Ivol, Sabrina","Shiver, John W","Spencer, Julia A","Van Hoof, Johan"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348165","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1089/hs.2020.0043","keywords":["covid-19","epidemic management/response","infectious diseases","sars-cov-2","vaccine development"],"topics":["Treatment"],"weight":1,"_version_":1666138495425445888,"score":109.48724},{"pmid":32420652,"title":"A nursing informatics response to COVID-19: perspectives from five regions of the world.","text":["A nursing informatics response to COVID-19: perspectives from five regions of the world.","The 21st century has seen several infectious disease outbreaks that have turned into epidemics and pandemics including Severe Acute Respiratory Syndrome (SARS) which began in Asia in 2003 (Poon, Guan, Nicholls, Yuen, & Peiris, 2004), followed by H1N1 that emerged in Mexico and the United States in 2009 (Belongia et al., 2010). Next came the lesser known Middle East Respiratory Syndrome (MERS) originating in Saudi Arabia in 2012 (Assiri et al., 2013), after which the Ebola outbreak in West Africa took place from 2014 to 2016, with a more recent occurrence in the Democratic Republic of Congo from 2018 to 2019 (Malvy, McElroy, de Clerck, Gunther, & van Griensven, 2019). To date, the coronavirus (COVID-19) outbreak that started in Wuhan, in the Hubei province of China, in late December 2019 seems to be eclipsing all of these previous infectious diseases in terms of its global reach and impact (Wang, Horby, Hayden, & Gao, 2020). After being declared by the World Health Organization (WHO) as a public health emergency on 30 January 2020 (World Health Organization, 2020c), it was elevated to a pandemic status on 11 March 2020 (World Health Organization, 2020d). As of 28 April 2020, there are more than 2.9 million cases and 202,597 deaths reported worldwide (World Health Organization, 2020b).","J Adv Nurs","Atique, Suleman","Bautista, John Robert","Block, Lorraine J","Lee, Jay Jung Jae","Lozada-Perezmitre, Erika","Nibber, Raji","O'Connor, Siobhan","Peltonen, Laura-Maria","Ronquillo, Charlene","Tayaben, Jude","Thilo, Friederike J S","Topaz, Maxim","32420652"],"abstract":["The 21st century has seen several infectious disease outbreaks that have turned into epidemics and pandemics including Severe Acute Respiratory Syndrome (SARS) which began in Asia in 2003 (Poon, Guan, Nicholls, Yuen, & Peiris, 2004), followed by H1N1 that emerged in Mexico and the United States in 2009 (Belongia et al., 2010). Next came the lesser known Middle East Respiratory Syndrome (MERS) originating in Saudi Arabia in 2012 (Assiri et al., 2013), after which the Ebola outbreak in West Africa took place from 2014 to 2016, with a more recent occurrence in the Democratic Republic of Congo from 2018 to 2019 (Malvy, McElroy, de Clerck, Gunther, & van Griensven, 2019). To date, the coronavirus (COVID-19) outbreak that started in Wuhan, in the Hubei province of China, in late December 2019 seems to be eclipsing all of these previous infectious diseases in terms of its global reach and impact (Wang, Horby, Hayden, & Gao, 2020). After being declared by the World Health Organization (WHO) as a public health emergency on 30 January 2020 (World Health Organization, 2020c), it was elevated to a pandemic status on 11 March 2020 (World Health Organization, 2020d). As of 28 April 2020, there are more than 2.9 million cases and 202,597 deaths reported worldwide (World Health Organization, 2020b)."],"journal":"J Adv Nurs","authors":["Atique, Suleman","Bautista, John Robert","Block, Lorraine J","Lee, Jay Jung Jae","Lozada-Perezmitre, Erika","Nibber, Raji","O'Connor, Siobhan","Peltonen, Laura-Maria","Ronquillo, Charlene","Tayaben, Jude","Thilo, Friederike J S","Topaz, Maxim"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420652","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jan.14417","locations":["Nicholls","Mexico","United States","Saudi Arabia","West Africa","McElroy","Wuhan","Hubei","China","Horby","Hayden"],"countries":["Saudi Arabia","China","Mexico","United States"],"countries_codes":["SAU|Saudi Arabia","CHN|China","MEX|Mexico","USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1667159284487553025,"score":100.47994},{"pmid":32400349,"title":"Identification of Falsified Chloroquine Tablets in Africa at the Time of the COVID-19 Pandemic.","text":["Identification of Falsified Chloroquine Tablets in Africa at the Time of the COVID-19 Pandemic.","Reports that chloroquine and hydroxychloroquine may be effective against COVID-19 have received worldwide attention, increasing the risk of the introduction of falsified versions of these medicines. Five different types of falsified chloroquine tablets were discovered between March 31, 2020 and April 4, 2020, in Cameroon and the Democratic Republic of Congo by locally conducted thin layer chromatographic analysis. Subsequent investigation by liquid chromatography and mass spectrometry in Germany proved the absence of detectable amounts of chloroquine and the presence of undeclared active pharmaceutical ingredients, that is, paracetamol and metronidazole, in four of the samples. The fifth sample contained chloroquine, but only 22% of the declared amount. Such products represent a serious risk to patients. Their occurrence exemplifies that once medicines or vaccines against COVID-19 may be developed, falsified products will enter the market immediately, especially in low- and middle-income countries (LMICs). Timely preparations for the detection of such products are required, including the establishment of appropriate screening technologies in LMICs.","Am J Trop Med Hyg","Gnegel, Gesa","Hauk, Cathrin","Neci, Richard","Mutombo, Georges","Nyaah, Fidelis","Wistuba, Dorothee","Hafele-Abah, Christine","Heide, Lutz","32400349"],"abstract":["Reports that chloroquine and hydroxychloroquine may be effective against COVID-19 have received worldwide attention, increasing the risk of the introduction of falsified versions of these medicines. Five different types of falsified chloroquine tablets were discovered between March 31, 2020 and April 4, 2020, in Cameroon and the Democratic Republic of Congo by locally conducted thin layer chromatographic analysis. Subsequent investigation by liquid chromatography and mass spectrometry in Germany proved the absence of detectable amounts of chloroquine and the presence of undeclared active pharmaceutical ingredients, that is, paracetamol and metronidazole, in four of the samples. The fifth sample contained chloroquine, but only 22% of the declared amount. Such products represent a serious risk to patients. Their occurrence exemplifies that once medicines or vaccines against COVID-19 may be developed, falsified products will enter the market immediately, especially in low- and middle-income countries (LMICs). Timely preparations for the detection of such products are required, including the establishment of appropriate screening technologies in LMICs."],"journal":"Am J Trop Med Hyg","authors":["Gnegel, Gesa","Hauk, Cathrin","Neci, Richard","Mutombo, Georges","Nyaah, Fidelis","Wistuba, Dorothee","Hafele-Abah, Christine","Heide, Lutz"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32400349","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.4269/ajtmh.20-0363","locations":["Cameroon","Germany"],"countries":["Cameroon","Germany"],"countries_codes":["CMR|Cameroon","DEU|Germany"],"e_drugs":["Hydroxychloroquine","Metronidazole","Chloroquine","Acetaminophen"],"topics":["Prevention"],"weight":1,"_version_":1666714494955421696,"score":100.15446}]}